Natera develops cell-free DNA testing platforms that enable genetic diagnostics across oncology, women's health, and transplant monitoring. The company's suite includes Panorama™ for prenatal screening, Signatera™ for personalized cancer detection and molecular residual disease monitoring, and Prospera™ for transplant surveillance. Its technology achieves analytical sensitivity down to a single molecule in a blood sample, allowing detection of disease markers at unprecedented resolution.
The company operates CLIA-certified laboratories in Austin, Texas and San Carlos, California, alongside CAP accreditation and ISO 13485 certification. Natera's work has generated more than 300 peer-reviewed publications and serves patients and healthcare providers across global markets. The organisation pursues a stated mission to establish personalized genetic testing as standard of care, positioning itself around earlier intervention and more targeted disease management through advanced diagnostics.
